Journal: Stem cell safeguards needed
A top scientific journal plans to adopt some stricter safeguards against fraud, in wake of a headline-grabbing South Korean cloning sham exposed a year ago.
The vast majority of cancer patients participating in studies of experimental drugs do not  care if the doctor running the study has financial ties to the drug's maker, according to a new survey that undermines "full disclosure" as a central tenet of clinical research.